Redx Pharma sees potential for RXC004 as a combination therapy

–News Direct–

Redx Pharma PLC (AIM:REDX) chief medical officer Dr Jane Robertson speaks to Proactive's Thomas Warner after announcing that phase II data from the first group of patients being administered RXC004 for biliary tract cancer was not enough to support further development.

Robertson highlights RXC004's potential for use as a combination therapy.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/redx-pharma-sees-potential-for-rxc004-as-a-combination-therapy-893660553